As 50% of melanomas harbor activating mutations in the BRAF gene (90% affect codon V600E) with consequent activation of the MAPK-ERK-signaling pathway, BRAF inhibitors, such as vemurafenib, dabrafenib, encorafenib, in combination with MEK-inhibitors (cobimetinib, trametinib, binimetinib) play an important role in the treatment of advanced melanoma [3]. This evidence concerns the gene MAP2K7 and melanoma.